Predictive biomarkers for the efficacy of nivolumab as ≥ 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial

Peer Review reports

Original Submission
24 Jan 2022	Submitted	Original manuscript
8 Feb 2022	Reviewed	Reviewer Report
22 Feb 2022	Reviewed	Reviewer Report
12 Mar 2022	Author responded	Author comments - Yoon-Koo Kang
Resubmission - Version 2
12 Mar 2022	Submitted	Manuscript version 2
14 Mar 2022	Author responded	Author comments - Yoon-Koo Kang
Resubmission - Version 3
14 Mar 2022	Submitted	Manuscript version 3
15 Mar 2022	Author responded	Author comments - Yoon-Koo Kang
Resubmission - Version 4
15 Mar 2022	Submitted	Manuscript version 4
24 Mar 2022	Reviewed	Reviewer Report
27 Mar 2022	Reviewed	Reviewer Report
Resubmission - Version 5
	Submitted	Manuscript version 5
Publishing
1 Apr 2022	Editorially accepted
9 Apr 2022	Article published	10.1186/s12885-022-09488-2

Back to article page